1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sanara MedTech shareholders approved the merger agreement with MiMedx Group at a special meeting on September 30, 2026, with 6,372,989 votes for and 1,944 against. Shareholders also approved, on an advisory basis, merger-related compensation for Sanara's named executive officers. The merger still depends on the expiration of the HSR Act waiting period and the satisfaction or waiver of other closing conditions.
Standard BioTools ended its agreement to sell its mass cytometry business to Multiplex Bio and agreed to sell it to Element Biosystems, a subsidiary of GMT Venture, for $5.5 million in cash. The company agreed to pay Multiplex Bio a $1.5 million termination fee, of which GMT Venture will pay $1.0 million, and says the Element deal increases its net cash position by about $15 million compared with the Multiplex Bio transaction, which the Treeline merger exchange ratio takes into account. Completion still depends on stockholder approval and the pending Treeline merger.
Multiplex Bio purchase agreement terminated on September 30, 2026; the company agreed to pay a $1.5 million termination fee, with GMT Venture paying $1.0 million of it on the company's behalf.
Element purchase price is $5.5 million in cash, on a cash-free and debt-free basis, with no financing condition and a GMT Venture equity commitment letter.
Closing requires stockholder approval and consummation of the Treeline merger; the company expects the Element deal to close by the end of 2026.
If the deal terminates in specified circumstances, the company owes Element a $1.0 million termination fee; expense reimbursements of up to $125,000 each apply if closing misses December 31, 2026 or March 31, 2027.
MacKenzie Realty Capital reported fiscal 2026 results for the year ended June 30, 2026, with net revenues down 9% and net loss down 41%. The same day, its Board temporarily suspended the Preferred Share Repurchase Program so it can react to strategic alternatives that its financial advisor, Maxim Group LLC, may bring. The Board says the company's issuance of common stock in exchange for preferred shares added selling pressure on the common stock, and it expects to reassess the program in due course.
Net revenues were $20.01 million for fiscal 2026, down 9% from $22.06 million in fiscal 2025.
Net loss was $14.13 million, down 41% from $23.97 million; net operating loss was $15.61 million, down 33% from $23.46 million.
The Preferred Share Repurchase Program is temporarily suspended; the Board expects to reassess it in due course.
The company says there can be no assurance that it will enter into any strategic transaction.
KLX Energy Services completed its subscription rights offering on September 29, 2026, selling 24,975,001 shares at $1.49 each for $37.2 million in gross proceeds. Backstop holders of its 2030 Notes exchanged them for 59,273,445 shares, cutting outstanding principal by $94.0 million, and the company expects 105,677,168 shares outstanding afterward, so existing shareholders will be diluted. The 2030 Notes indenture was also amended to loosen leverage tests, which gives the company more covenant flexibility.
Rights offering: 24,975,001 shares sold at $1.49 per share for $37.2 million gross; $31.0 million for general corporate purposes and $6.2 million to redeem 2030 Notes at par on October 10, 2026
Backstop exchange: 59,273,445 shares issued to Backstop Parties; 2030 Notes principal reduced by $94.0 million; 105,677,168 shares expected outstanding
Indenture amended: total net leverage incurrence test relaxed from 2.50:1.00 to 3.00:1.00; maintenance covenant step-down reset to 4.50:1.00 starting with the quarter ending September 30, 2026
Levi Strauss & Co. named John Vandemore, former CFO of Skechers U.S.A., as Executive Vice President and Chief Financial Officer, effective November 1, 2026. He succeeds the role currently held by Harmit Singh, who announced his retirement in April 2026 and will serve as a Special Advisor through November 30, 2026, to support the transition.
Vandemore, 53, was CFO of Skechers U.S.A., Inc. starting November 2017 and previously held finance roles at Mattel and other firms
Base salary of $1,350,000 with an initial target bonus of 110% of base salary
Sign-on award includes a $4,000,000 cash incentive, plus RSU and SAR grants valued at $5,500,000 each
Reed's entered an amendment to its senior secured loan with Whitebox-affiliated lenders and Cantor Fitzgerald as agent, converting its revolving credit commitments into $9.25 million of term loans that cannot be re-borrowed once repaid. The amendment raises the interest rate to 8.75% from 8.00%, extends maturity to June 30, 2027, and adds a new Event of Default requiring at least $10 million of cash equity contributions by November 6, 2026, which matters to shareholders because it signals tighter financing terms and a near-term capital requirement.
Revolving credit commitments converted into $9.25 million in term loans, effective September 30, 2026
Interest rate on term loans rises to 8.75% per annum from 8.00%; optional extension period accrues at 9.25%
Maturity extended to June 30, 2027, with an optional three-month extension to September 30, 2027
New Event of Default requires at least $10 million in cash equity contributions by November 6, 2026; inventory plus receivables liquidity covenant waived through that date
Grindr agreed on September 30, 2026 to acquire PurposeMed Inc., the parent company of the Freddie telehealth PrEP brand, for a base price of $250 million, consisting of $190 million in cash and $60 million in Grindr common stock. The deal also includes an earnout of up to $70 million in cash tied to PurposeMed's fiscal 2027 financial targets. Grindr said the acquisition is expected to have an immaterial impact on its 2026 financial results, and the deal is expected to close in Q4 2026, subject to closing conditions.
Base price of $250 million: $190 million in cash and $60 million in stock, or 3,851,684 shares valued at $15.58 per share
Earnout of up to $70 million in cash, tied to 2027 performance targets and payable in 2028
Freddie expects 2026 revenue of more than $80 million and Adjusted EBITDA of more than $10 million
Expected close in Q4 2026; either party may terminate if closing has not occurred by December 30, 2026
TScan Therapeutics said its Chief Financial Officer, Jason A. Amello, and Chief Medical Officer, Chrystal Louis, will leave the company as part of a strategic reorganization. Both executives signed separation agreements, with employment ending on the earlier of November 1, 2026 or the date they start other paid work, and their pay and benefits continue until then.
Jason A. Amello (CFO) and Chrystal Louis, M.D., MPH (CMO) are departing under separation agreements dated September 24 and September 25, 2026.
Employment ends on the earlier of November 1, 2026 or the executive's start of other employment, consulting or paid board service.
Amello may receive a $85,000 lump-sum cash award and Louis a $125,000 award, each payable if a company milestone is achieved before their separation date under the November 2025 retention program.
Exascale Labs (XLAB) appointed Jake Carney as Chief Financial Officer effective September 25, 2026, ending the interim tenure of Gildas Bonnier, whose service was no longer required after the company's formal search. The filing states Bonnier's departure was not due to any disagreement with the company over operations, policies or practices.
Jake Carney, 38, appointed CFO effective September 25, 2026
Gildas Bonnier ceased serving as Interim CFO effective September 25, 2026
Carney's base salary is $6,000 per month under his employment agreement
Filing states no disagreement led to Bonnier's departure
On September 29, 2026, BioStem Technologies agreed to sell 735,296 shares at $4.08 per share, with Series A and Series B warrants, for approximately $3.0 million in gross proceeds before fees; the deal closed September 30, 2026. The filing also says a $10.0 million Clearance Payment owed to BioTissue, due by September 15, 2026, has not been made, and the company is in ongoing talks about its timing and terms. Shareholders face potential dilution from the new shares and warrants, along with an unpaid obligation.
735,296 shares at $4.08 per share, plus Series A and Series B warrants each for up to 735,296 shares at a $3.83 exercise price
Gross proceeds of approximately $3.0 million before placement agent fees; H.C. Wainwright received a cash fee of 7.0% of gross proceeds
Private placement closed September 30, 2026; resale registration statement due within 30 calendar days of the registration rights agreement
$10.0 million Clearance Payment to BioTissue was due by September 15, 2026 and had not been paid as of the filing date
MSG Knickerbockers entered into agreements on September 30, 2026 to separate its New York Rangers hockey business into MSG Rangers Corp., which will be distributed to its stockholders. The company keeps sole discretion over whether to proceed, and the distribution is expected on October 26, 2026, after which shareholders will hold shares in both companies.
Record date is October 20, 2026; distribution is expected October 26, 2026.
Holders receive one MSG Rangers share for every two shares of MSG Sports common stock held at the record date.
Regular way trading of MSG Knicks (MSGK) and MSG Rangers (MSGR) is expected to begin October 27, 2026.
Completion depends on effectiveness of the Form 10, certain conditions, final league approval and a tax opinion.
Health In Tech said full-year 2026 revenue is expected to be about $33 million, roughly in line with 2025 revenue, and attributed the outlook mainly to the timing of several strategic initiatives. The company also launched HitRix, an AI-powered platform for large-group self-funded health insurance submissions, and said it expects HitRix and related initiatives to contribute more meaningfully beginning in 2027.
2026 revenue outlook of approximately $33 million, roughly in line with 2025 revenue
Outlook reflects timing of HitRix commercialization, the Three-Year Rate Stabilization Program and additional carrier capacity
HitRix platform launched September 30, 2026, for large-group self-funded health insurance workflows
Distribution ecosystem included 933 partners as of June 30, 2026, up 19.9% year over year
TTM Technologies completed its acquisition of Epiq Solutions on September 30, 2026, paying approximately $1.1 billion in cash, subject to customary adjustments. The purchase was funded with new term loans under a Third Amended and Restated Credit Agreement and proceeds from the company's 6.750% senior notes due 2034. The company expects the deal to be immediately accretive to adjusted EBITDA, moderately dilutive to non-GAAP diluted EPS in 2027, and accretive to non-GAAP diluted EPS in 2028.
Purchase price of approximately $1.1 billion in cash, paid to the seller on September 30, 2026, subject to working capital and other adjustments
New incremental facilities of $300 million term loan A and $800 million seven-year term loan B, with JPMorgan Chase Bank, N.A. as administrative agent
Company expects immediate accretion to adjusted EBITDA, moderate dilution to non-GAAP diluted EPS in 2027, and accretion in 2028
Outlook Therapeutics received a Nasdaq notice on September 25, 2026, stating its stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, but the company has until March 24, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.
Nasdaq notice dated September 25, 2026 cites a closing bid below $1.00 for 30 consecutive business days under Listing Rule 5550(a)(2)
Compliance Date is March 24, 2027, 180 calendar days under Rule 5810(c)(3)(A)
Company may be eligible for a second 180-day period and may need a reverse stock split; if not compliant, Nasdaq would issue a delisting notice that the company could appeal
Alamo Group said on September 29, 2026 that, as part of a review of its product portfolio, it will stop producing its Dixie Chopper branded line. The company estimates $15.0 million to $20.0 million in charges in the third quarter of 2026, including $1.0 million to $4.0 million in cash costs for inventory returns, purchase commitments and related items. The charges are estimates that depend on factors such as the net realizable value of inventory and equipment returns, and the company may record other unanticipated charges.
Company will cease production of its Dixie Chopper branded product line, decided September 29, 2026
Estimated total charges of $15.0 million to $20.0 million expected in the third quarter of 2026
Approximately $1.0 million to $4.0 million of the charges are expected to be cash expenditures
Estimates are subject to assumptions and may change; additional charges are possible
Albertsons Companies appointed three new directors, William Boltz, Chris Drumgoole and Margaret Ham, effective October 14, 2026, expanding the board from 11 to 14 members. The company also named Senior Vice President Cody Perdue as Interim Chief Financial Officer effective September 30, 2026, after Sharon McCollam's previously announced retirement, so shareholders are seeing a change in the finance leadership while a permanent CFO is sought.
Three directors appointed effective October 14, 2026: William P. Boltz, Chris Drumgoole and Margaret M. Ham; board expands from 11 to 14 directors
Cody Perdue, SVP of Treasury, Investor Relations and Risk Management, named Interim CFO effective September 30, 2026
Perdue receives a stipend at an annual rate of $350,000 during his interim service, in addition to his normal compensation
Sharon McCollam stays in an advisory role through the end of the fiscal year on February 27, 2027; the search for a permanent CFO is underway
On September 29, 2026, Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated up to $24.8 million, subject to post-closing reconciliation and payable in six installments. The filing also discloses a supply agreement with Rotech and a conditional increase in the share repurchase authorization to $45.0 million, effective only if the sale closes, which matters to shareholders because it removes a business with declining revenue while expanding capital return.
Purchase price is estimated at up to approximately $24.8 million, payable in six installments and subject to post-closing reconciliation.
The rental business generated $24.3 million of revenue in the first half of 2026, down 9.8% year over year.
Share repurchase authorization would rise from $30.0 million to $45.0 million and expire June 30, 2028 instead of December 31, 2027, but only upon closing.
The transaction is expected to close in the fourth quarter of 2026, and the rental business will be reported as discontinued operations starting with third-quarter 2026 results.
Progress Software reported fiscal third-quarter 2026 revenue of $246 million, down 2% year-over-year, while GAAP diluted earnings per share rose 25% to $0.55. The company raised its fiscal 2026 revenue and non-GAAP EPS guidance but cut its GAAP EPS guidance and expects a GAAP loss per share in the fourth quarter, and it closed its acquisition of Domo's AI and data platform business.
Q3 revenue was $246 million, down 2% year-over-year; ARR was $873 million, up 1% on a constant currency basis.
Fiscal 2026 revenue guidance was raised to $1,044 million-$1,052 million from $990 million-$1,002 million; GAAP diluted EPS guidance was cut to $1.18-$1.28 from $1.60-$1.74.
Fourth-quarter 2026 GAAP diluted loss per share is guided at $(0.41) to $(0.32); non-GAAP diluted EPS is guided at $1.24 to $1.33.
Q3 non-GAAP diluted EPS was $1.69, up 13% from $1.50; cash and cash equivalents were $113.7 million at quarter end.
Cars.com said CFO Sonia Jain will leave the role effective November 6, 2026, and stay on as an Executive Advisor until March 31, 2027. Trent Ziegler, former CFO of FairSquare, will become CFO on November 6, 2026, after joining as CFO-Designate on October 19, 2026. The change is a senior finance leadership transition, and the filing discloses no financial results or guidance changes.
Sonia Jain ceases to be CFO effective November 6, 2026; she receives $250,000 during her advisory period through March 31, 2027
Trent Ziegler, age 43, previously CFO of FairSquare, Inc. (August 2024 to September 2026) and earlier CFO of LendingTree, Inc.
Ziegler compensation: $475,000 base salary, 80% bonus target, $3,500,000 target-value RSU grant, and a $275,000 signing bonus
Micron reported fiscal fourth-quarter 2026 revenue of $54.23 billion, up from $41.46 billion in the prior quarter and $11.32 billion a year earlier, with GAAP diluted earnings per share of $32.87. The company also guided first-quarter fiscal 2027 revenue to $61.5 billion, plus or minus $1.5 billion, and GAAP diluted earnings per share to $37.84, plus or minus $1.00, both above fourth-quarter levels. For shareholders, the filing shows sharply higher sales and profit and a higher outlook, and the company's forward-looking statements carry the risks described in its SEC filings.
Fiscal Q4 2026 revenue was $54.23 billion; GAAP net income was $37.70 billion, or $32.87 per diluted share
Fiscal 2026 revenue was $133.19 billion, up from $37.38 billion in fiscal 2025; GAAP net income was $84.97 billion
Q1 fiscal 2027 guidance: revenue of $61.5 billion plus or minus $1.5 billion; GAAP diluted EPS of $37.84 plus or minus $1.00
Board declared a quarterly dividend of $0.15 per share, payable October 29, 2026, to holders of record on October 14, 2026
Carlsmed said CFO Leo Greenstein left the role effective September 25, 2026, and appointed Richard Heppenstall as CFO effective September 28, 2026. Greenstein's separation includes $500,000 in cash severance, accelerated vesting of some equity awards, and a $60,000 advisory fee through December 31, 2026. The company reaffirmed its full-year 2026 revenue guidance of $74 million to $78 million, so the leadership change did not come with a change to that outlook.
Greenstein's departure effective September 25, 2026; Heppenstall's appointment effective September 28, 2026.
Greenstein to receive $500,000 in cash payments, equal to 12 months of base salary, plus a $60,000 advisory fee.
Heppenstall's employment agreement sets a $500,000 base salary and a target bonus of 60% of base, with $1.4 million each in inducement stock options and RSUs.
Full-year 2026 revenue guidance of $74 million to $78 million was reaffirmed.
Mattel's CEO Ynon Kreiz resigned as CEO and chairman effective October 2, 2026, and the board named director Roger Lynch as chairman effective that date and as CEO no later than November 2, 2026. Jonathan Anschell will serve as interim principal executive officer until Lynch takes over, and the filing discloses Lynch's pay package, including a $2,300,000 base salary and $10,600,000 make-whole signing bonus.
Ynon Kreiz resigned as CEO and chairman effective October 2, 2026, to take a senior role at another public company
Roger Lynch, a board member since 2018, becomes chairman October 2, 2026 and CEO no later than November 2, 2026
Lynch's offer letter includes a $2,300,000 base salary, a 200% target bonus, and a $10,600,000 make-whole signing bonus
Diana Ferguson was named Independent Lead Director effective October 2, 2026
Trump Media & Technology Group (TMTG) and TAE Technologies signed an amended and restated convertible promissory note that replaces a December 18, 2025 note tied to their pending all-stock merger. The amended note carries an initial $200 million first tranche, allows up to an additional $100 million second tranche, and caps total principal at $300 million plus PIK interest, so TMTG's financial exposure to TAE rises if the second tranche is drawn. The companies also filed a Form S-4 registration statement for the merger, which has not yet become effective.
First tranche principal is $200 million; TAE may request up to $100 million more during a second tranche draw period.
Second tranche draw period ends on the earlier of November 29, 2026 or termination of the merger agreement; each drawdown must be at least $50 million.
Interest accrues at 7% per year and is paid in kind by adding to principal; accrued interest under the note was $10,969,863.01 as of signing.
The note converts automatically on a qualified TAE financing of at least $300 million, and TMTG gets pre-conversion voting rights tied to 25% of the outstanding amount.
PowerCompute said its Bitcoin-backed credit facility with Arch Lending was settled on September 24, 2026, its scheduled reset date, and was not triggered by a margin call or forced liquidation. The company says secured debt fell about 94%, from about $19.4 million at June 30, 2026 to about $1.25 million, and that no Bitcoin remains pledged, which it expects to lower interest and collar-related expense.
Arch facility settled September 24, 2026, with $21,892,132 principal, $118,582 accrued interest and a $440,122 fee covered by sale of about 267.3 of 307 pledged Bitcoin
About 39.6 Bitcoin returned to the company; no Bitcoin remains pledged as collateral
Secured debt fell from about $19.4 million at June 30, 2026 to about $1.25 million, a reduction of about 94%
Remaining secured promissory note matures December 31, 2026 and is not secured by Bitcoin
General Mills' board elected Chief Operating Officer Dana McNabb as chief executive, succeeding Jeffrey Harmening, who is retiring as CEO and will serve as Executive Chair of the board. Both appointments take effect January 1, 2027, and the board also set new pay levels for each executive.
McNabb's CEO base salary will be $1,350,000, with an annual cash incentive target of 180% of base salary, plus an incremental long-term incentive award of $2,100,000.
Harmening's base salary as Executive Chair will be reduced to $1,100,000, and his annual cash incentive target will decrease to 125% of base salary.
McNabb has been Chief Operating Officer since June 2026 and joined General Mills in 1999.
Jabil reported preliminary, unaudited fourth-quarter fiscal 2026 net revenue of $10.6 billion, up from $8.25 billion a year earlier, and U.S. GAAP diluted EPS of $3.76, up from $1.99. The company also guided fiscal 2027 net revenue to $44.5 billion and core diluted EPS to $17.55, and expects first-quarter fiscal 2027 revenue of $10.6 billion to $11.4 billion, which points to continued growth for shareholders if the outlook holds.
Q4 fiscal 2026 net revenue $10.6 billion vs. $8.25 billion a year earlier; U.S. GAAP diluted EPS $3.76 vs. $1.99
Fiscal 2026 net revenue $36.0 billion; core diluted EPS $13.09 vs. $9.75 in fiscal 2025
Rafael Holdings said its Phase 3 TransportNPC trial of Trappsol Cyclo in 94 patients with Niemann-Pick Disease Type C did not achieve statistical significance on the primary endpoint, with a 64% slowing of disease progression versus placebo at Week 96 (p=0.19). A prespecified analysis of patients on background miglustat and/or leucine, about 83% of the study population, was statistically significant (p=0.046), and the company said it remains on track to submit an NDA to the FDA in the fourth quarter of 2026.
Primary endpoint missed statistical significance: difference of -0.81 points, 95% CI -2.04 to 0.41, p=0.19
Prespecified subgroup (n=78) on background miglustat and/or leucine showed a 71% slowing of progression, p=0.046
Serious treatment-emergent adverse events were 35.9% with Trappsol Cyclo versus 16.7% with placebo; one severe bilateral deafness event was reported
NDA submission to the FDA remains planned for the fourth quarter of 2026; investor call held September 30 at 8:30 a.m. ET
Moderna appointed Juan Andres, a former Moderna executive who retired in 2023, as its new Chief Operating Officer, effective October 5, 2026, reporting to CEO Stephane Bancel. The company also said Chief Technical Operations and Quality Officer Jerh Collins will retire, so the appointment adds a senior operations role while a manufacturing leader departs.
Juan Andres, 62, starts as COO on October 5, 2026 and will serve on the Executive Committee.
Andres receives an initial base salary of $800,000 and a target annual bonus of 90% of base salary.
A new hire equity award with total value of $5,000,000 is subject to four-year vesting; annual equity target is $4,000,000 to $5,000,000.
Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire; the filing gives no retirement date.
Connect Biopharma reported preliminary topline results from its Phase 2 Seabreeze STAT COPD study of rademikibart as an add-on treatment for acute COPD exacerbations, with 159 participants randomized 1:1. The primary endpoint, treatment failure through Week 4, was reduced 81% versus placebo (p=0.0122), but the key secondary FEV1 result at Week 4 (70 mL improvement, p=0.1607) was not statistically significant. The company plans to engage the FDA on a Phase 3 program, and no timing was given.
Treatment failure through Week 4 was reduced 81% versus placebo (p=0.0122); 2 of 78 rademikibart participants and 11 of 81 placebo participants experienced treatment failure
FEV1 improved 70 mL at Week 4 versus placebo, but the result was not statistically significant (p=0.1607)
Any treatment-emergent adverse event occurred in 11 (14.1%) rademikibart participants versus 21 (25.9%) placebo participants
Connect plans to engage the FDA on a Phase 3 program; the filing gives no timing for that engagement
On September 29, 2026, Capital Bancorp agreed to merge into Peoples Bancorp in an all-stock deal, with each Capital share converting into 1.11 Peoples shares. The companies put the aggregate transaction value at about $728.1 million, or $43.75 per Capital share, and expect the deal to close in the first half of 2027, subject to regulatory and shareholder approvals. Capital shareholders would hold about 32% of the combined company.
Each Capital share converts into 1.11 Peoples shares; aggregate value about $728.1 million, or $43.75 per share, based on Peoples' 20-day volume-weighted average price of $39.41 as of September 29, 2026.
Capital must pay Peoples a termination fee of $30.66 million in certain specified circumstances.
Former Capital shareholders are expected to own about 32% of Peoples; three Capital directors are expected to join the Peoples board.
Closing is expected in the first half of 2027; Capital directors and executive officers signed support agreements to vote in favor of the merger.
The Hartford Insurance Group said CEO Christopher Swift will leave the chief executive role effective March 1, 2027, and become executive chair while still chairing the board. President A. Morris Tooker, who joined in 2015, will become CEO on the same date and joins the board October 1, 2026. Tooker's proposed target pay is $12 million a year, and the change is a planned succession rather than a reported change in financial results.
Swift resigns as CEO effective March 1, 2027; expected to step down as executive chair in the second half of 2027
Tooker, 57, named CEO effective March 1, 2027 and elected director effective October 1, 2026
Tooker target total annual compensation of $12 million: $1.1 million base salary, $2.75 million AIP target, $8.15 million LTI target
Swift 2027 base salary of $1.2 million, AIP target of $2.4 million and LTI target of $7.4 million
Hormel Foods agreed on September 29, 2026 to acquire all outstanding membership interests of Brakebush Brothers, LLC, a value-added chicken company, for a base price of $1.055 billion in cash, subject to customary adjustments. The deal is expected to close in the first quarter of Hormel's fiscal 2027, subject to antitrust waiting periods and other closing conditions, and the company expects it to be accretive to adjusted earnings per share beginning in fiscal 2028.
Base purchase price of $1.055 billion in cash, subject to customary adjustments
Brakebush generated approximately $1.2 billion in net sales over the last 12 months, per the press release
Expected closing in the first quarter of fiscal 2027; either party may terminate if not completed by March 29, 2027, with a possible three-month extension
Company plans to finance the deal with a combination of cash on hand and long-term debt and expects run-rate cost synergies of about $20 million by the end of fiscal 2028
Marygold Companies said that on September 25, 2026, it signed a merger agreement under which funds managed by Madison Dearborn Partners will acquire all outstanding shares for $2.00 each. Holders of about 75% of the voting power approved the deal by written consent, so the company can no longer respond to or accept alternative acquisition proposals.
Merger agreement signed September 25, 2026; funds managed by Madison Dearborn Partners to acquire all outstanding shares at $2.00 per share
Holders of approximately 75% of voting power approved the agreement by written consent shortly after signing
Special Committee and Board unanimously determined the merger agreement is advisable, fair to and in the interests of the company
Full details of the prior sale process will be included in an information statement to be filed with the SEC and mailed to stockholders
Cal-Maine Foods reported a net loss attributable to the company of $58.6 million, or $1.26 per diluted share, for the first quarter ended August 29, 2026, compared with net income of $199.3 million, or $4.12 per diluted share, a year earlier. Net sales fell 41.5% to $539.6 million, mainly because conventional shell egg prices dropped sharply, and the company will pay no cash dividend for the quarter.
Net sales were $539.6 million, down from $922.6 million, a decrease of 41.5%.
Operating loss was $82.2 million, compared with operating income of $249.2 million a year earlier.
Conventional Shell Eggs segment loss was $71.0 million, with average selling price per dozen down 59.3%.
No cash dividend for the quarter; cumulative loss to recover before a future dividend was $94.5 million as of August 29, 2026.
OceanLight Acquisition Corp, a special purpose acquisition company listed on Nasdaq, entered into a merger agreement on September 28, 2026 with AIRE Inc., a Cayman Islands home textile and green sleep technology company. AIRE would become a wholly owned subsidiary of a new publicly traded holding company, with AIRE shareholders receiving shares valued at $1.0 billion. The deal is subject to shareholder approvals, an SEC-effective registration statement and Nasdaq listing approval, so completion is not assured.
Agreement signed September 28, 2026; AIRE shareholders to receive 100,000,000 Purchaser ordinary shares valued at $10.00 per share, based on a $1.0 billion Company net value
Post-closing board of Purchaser expected to have five directors, all designated by AIRE, three of them independent under Nasdaq rules
Either party may terminate if closing has not occurred by August 10, 2027; a $500,000 break-up fee applies in certain termination circumstances
Closing requires approval by both OceanLight and AIRE shareholders, effectiveness of a Form F-4 registration statement and Nasdaq listing approval
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.